×
SciSparc Receivables 2017-2024 | SPRC
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
SciSparc receivables from 2017 to 2024. Receivables can be defined as the total amount of collectibles for a company
View More
SciSparc Receivables 2017-2024 | SPRC
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
SciSparc receivables from 2017 to 2024. Receivables can be defined as the total amount of collectibles for a company
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$70.5B
Zoetis (ZTS)
$69.4B
Takeda Pharmaceutical (TAK)
$49.4B
Daiichi Sankyo, - (DSNKY)
$48.3B
BeOne Medicines - (ONC)
$34.4B
Sandoz Group AG (SDZNY)
$27.6B
Summit Therapeutics (SMMT)
$19.5B
Merck (MKKGY)
$17B
Shionogi (SGIOY)
$14.9B
United Therapeutics (UTHR)
$14.1B
Neurocrine Biosciences (NBIX)
$13.4B
IPSEN (IPSEY)
$11.4B
Orion OYJ (ORINY)
$11.3B
Eisai (ESAIY)
$9.3B
Madrigal Pharmaceuticals (MDGL)
$9.2B
Corcept Therapeutics (CORT)
$7.4B
Grifols, S.A (GRFS)
$7B
Stevanato Group S.p.A (STVN)
$6.9B
Ionis Pharmaceuticals (IONS)
$6.8B
Ono Pharmaceutical (OPHLF)
$5.7B
Hikma Pharmaceuticals Plc (HKMPF)
$5.4B
Soleno Therapeutics (SLNO)
$3.6B
Procaps Group, S.A (PROCF)
$3.2B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$3B
Crinetics Pharmaceuticals (CRNX)
$2.9B
NewAmsterdam Pharma (NAMS)
$2.8B
Catalyst Pharmaceuticals (CPRX)
$2.6B
Hypermarcas (HYPMY)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2.3B
Ocular Therapeutix (OCUL)
$2.1B